Twist Bioscience Corporation (TWST) key performance indicators and operating metrics (25 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Customers shipped products to | 2.58K | FY2026-Q2 |
| DNA Synthesis and Protein Solutions (DSPS) revenue | 53.3M | FY2026-Q2 |
| NGS Applications revenue | 57.4M | FY2026-Q2 |
| Genes physically shipped | 300K | FY2026-Q2 |
| Twist Bioscience Revenue | 103.7M | FY2026-Q1 |
| Twist Bioscience Cash, Cash Equivalents and Short-term Investments | 198M | FY2026-Q1 |
| Cost of revenues | 48.2M | FY2025-Q4 |
| Twist Bioscience Biopharma Solutions Revenue | 6.4M | FY2025-Q4 |
| Twist Bioscience NGS Read Revenue | 53M | FY2025-Q4 |
| Twist Bioscience SynBio Write Revenue | 39.5M | FY2025-Q4 |
| Adjusted EBITDA (non-GAAP) | -7.8M | FY2025-Q4 |
| Twist Bioscience Biopharma Solutions Orders | 11.5M | FY2025-Q4 |
| Twist Bioscience Biopharma Solutions Growth YoY | 22.00 percent | FY2025-Q4 |
| Twist Bioscience NGS Read Growth YoY | 16.00 percent | FY2025-Q4 |
Back to TWST overview · TWST earnings · TWST holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.